Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Jan Nilsson

Professor

Default user image.

Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100.

Author

  • Åsa Ström
  • Gunilla Nordin Fredrikson
  • Alexandru Schiopu
  • Irena Ljungcrantz
  • Ingrid Söderberg
  • Bo Jansson
  • Roland Carlsson
  • Anna Hultgårdh
  • Jan Nilsson

Summary, in English

Objective: The immune system plays an important regulatory role in the development of atherosclerotic plaques and neointima formation following various types of angioplasty. In the present study we investigated the effect of antibodies against aldehyde-modified apolipoprotein B-100 (apoB-100), a component of oxidized LDL, on atherosclerosis and response to arterial injury in mice. Methods: The ability of a high affinity human recombinant antibody (21303), specific for malondialdehyde-modified apoB-100, to influence formation of atherosclerosis as well as remodelling and neointima formation after a collar-induced injury of the carotid artery was studied in LDL receptor(-/-) mice over-expressing human apoB-100. Results: The antibody recognized epitopes present in mouse plasma and reduced the plasma level of oxidized LDL by 34%. Antibody treatment inhibited injury-induced restrictive vascular remodelling but did not influence the size of the neointima. Atherosclerosis in the uninjured contra lateral carotid artery was determined by computerized image analysis and the mean plaque area in animals given control IgG1 was 7608 +/- 10,336 mu m(2). In contrast, essentially no plaques were present in animals treated with the 2DO3 antibody (397 +/- 235 mu m(2), P < 0.0 1 versus control IgG 1). Conclusions: Treatment with antibodies against aldehyde-modified apoB-100 dramatically reduces atherosclerosis and inhibits restrictive vascular remodelling in mice expressing human apoB-100. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

Department/s

  • Vessel Wall Biology
  • Cardiovascular Research - Immunity and Atherosclerosis

Publishing year

2007

Language

English

Pages

298-305

Publication/Series

Atherosclerosis

Volume

190

Issue

2

Document type

Journal article

Publisher

Elsevier

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • atherosclerosis
  • oxidized LDL
  • apolipoprotein B-100
  • antibodies
  • vascular injury

Status

Published

Research group

  • Vessel Wall Biology
  • Cardiovascular Research - Immunity and Atherosclerosis

ISBN/ISSN/Other

  • ISSN: 1879-1484